about
Identifying Recent HIV Infections: From Serological Assays to GenomicsA Comparison of South African National HIV Incidence Estimates: A Critical Appraisal of Different MethodsIncident Infection and Resistance Mutation Analysis of Dried Blood Spots Collected in a Field Study of HIV Risk Groups, 2007-2010A general HIV incidence inference scheme based on likelihood of individual level data and a population renewal equation.Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository.Incorporating incidence information within the UNAIDS Estimation and Projection Package framework: a study based on simulated incidence assay data.Mixture models for calibrating the BED for HIV incidence testing.How should we best estimate the mean recency duration for the BED method?Evaluation of a multiplex assay for estimation of HIV-1 incidence.Recalibration of the limiting antigen avidity EIA to determine mean duration of recent infection in divergent HIV-1 subtypesComparison of antibody responses to HIV infection in Ugandan women infected with HIV subtypes A and D.Assessing Biases in the Evaluation of Classification Assays for HIV Infection Recency.Mean Recency Period for Estimation of HIV-1 Incidence with the BED-Capture EIA and Bio-Rad Avidity in Persons Diagnosed in the United States with Subtype B.Analysis of Viral Diversity in Relation to the Recency of HIV-1C Infection in BotswanaComparison of cross-sectional HIV incidence assay results from dried blood spots and plasma.Improvements in the continuum of HIV care in an inner-city emergency department.Estimation of HIV incidence using multiple biomarkers.Short Communication: Defining optimality of a test for recent infection for HIV incidence surveillanceThe HIV epidemic in Southern Africa - Is an AIDS-free generation possible?False Recent Ratio of the Limiting-Antigen Avidity Assay and Viral Load Testing Algorithm Among Cameroonians with Long-Term HIV Infection.Moving towards a reliable HIV incidence test - current status, resources available, future directions and challenges ahead.Strengthening HIV surveillance: measurements to track the epidemic in real time.Infection Staging and Incidence Surveillance Applications of High Dynamic Range Diagnostic Immuno-Assay Platforms.HCV avidity as a tool for detection of recent HCV infection: sensitivity depends on HCV genotype.The HIV Genomic Incidence Assay Meets False Recency Rate and Mean Duration of Recency Infection Performance Standards.Short Communication: Comparison of Maxim and Sedia Limiting Antigen Assay Performance for Measuring HIV Incidence.Evaluation of the limiting antigen avidity EIA (LAg) in people who inject drugs in Greece.Viral load criteria and threshold optimization to improve HIV incidence assay characteristicsHIV-1 incidence among people seeking voluntary counseling and testing centers, including pregnant women, in Pernambuco State, Northeast Brazil.Development and Evaluation of a Modified Fourth-Generation Human Immunodeficiency Virus Enzyme Immunoassay for Cross-Sectional Incidence Estimation in Clade B Populations.Use of Hepatitis C Virus (HCV) Immunoglobulin G Antibody Avidity as a Biomarker to Estimate the Population-Level Incidence of HCV InfectionA comparison of self-report and antiretroviral detection to inform estimates of antiretroviral therapy coverage, viral load suppression and HIV incidence in Kwazulu-Natal, South Africa.Assays for estimating HIV incidence: updated global market assessment and estimated economic value.Cross-Sectional HIV Incidence Surveillance: A Benchmarking of Approaches for Estimating the 'Mean Duration of Recent Infection'.Population-level HIV incidence estimates using a combination of synthetic cohort and recency biomarker approaches in KwaZulu-Natal, South Africa
P2860
Q26778001-EBD55BFA-436A-4A46-AE06-8E56D728C5DDQ28546966-4A0E78DC-D7FD-49A3-96D8-167916E3EFE1Q28552613-7D89617D-A72D-4204-8516-D4A40C167575Q30566307-02B7DB1F-5D2B-4BD0-987A-46AA4A56BA44Q30596338-4782AF6F-BCF9-4736-B138-819DC9B3856BQ30870458-12E3A528-E94A-4728-B70D-5C542D35122EQ33924641-D1E328F5-95F1-4FA3-A311-313F46BDF1EEQ34482675-FA80C9DF-3E3E-4AED-B558-5383752EC4F9Q34745421-97F6CDF0-9D3E-4947-A18E-C5442F078593Q35119643-393D97C9-57DC-4CA9-85F2-E732FE759E01Q35230246-8D4068CF-94FD-42D4-B3E4-2A66537B344BQ35799203-4C93DCE9-5799-4B53-B4D1-6041EC98E189Q35985816-8B17E79F-8D13-4E07-86E6-4654ECA0B4DDQ36110367-63A2339D-3B95-4FC3-A61D-266821CC7279Q36288430-FC94731E-6F99-4E7D-AFA1-DD7641A15AD7Q36438781-28DF8B92-42E3-42A0-BB4E-F0E90892C488Q36764936-71B4D574-DF2A-4280-8179-064821765109Q37460199-210700D3-3373-475E-843C-53492FFEEDD4Q38199989-23C7A00B-9B3C-4085-9359-C8697B167E21Q38697223-A22C1FFE-95BA-452D-B4AF-B08000BC014BQ38779402-43060388-D14C-4EFE-BF3B-60B22E776715Q38843374-AF7B5CF6-3085-481B-BDF6-931CA98E1AB7Q40044059-38719F17-1E64-43DA-A23C-1EDB45D3C823Q40069643-1C5D8A24-1456-4493-B80D-162769483F8BQ40091554-833FFEE6-2BC4-4F68-A529-46E38C442A84Q40285384-15552B03-BBD2-4D04-95FF-ED54491C133AQ40485453-08E3DD7C-2488-4B13-9959-0A406BBC1C25Q40601041-6E197626-6FF7-4862-84FF-C59ABFB9E4A7Q40709057-30FF8EAC-E76B-4A0C-9A6C-2C359763E4FCQ40751062-CD6D3845-4884-4446-ACD2-909C04E77AC7Q40832940-A69B7539-8FFC-4B14-9BAE-A25F7249C1EEQ41926207-0B4CFBA2-9C45-4498-850F-680CE42CFEECQ48253997-0BC58C72-B1DE-40A1-812B-73AD07AEF55EQ53274310-1F984476-41BD-4E92-B052-E5054006DBF4Q56908720-1E8A1867-20A3-476B-AB91-AE633BAB3361
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
A new general biomarker-based incidence estimator.
@ast
A new general biomarker-based incidence estimator.
@en
type
label
A new general biomarker-based incidence estimator.
@ast
A new general biomarker-based incidence estimator.
@en
prefLabel
A new general biomarker-based incidence estimator.
@ast
A new general biomarker-based incidence estimator.
@en
P2860
P50
P1433
P1476
A new general biomarker-based incidence estimator.
@en
P2093
Alex Welte
P2860
P304
P356
10.1097/EDE.0B013E3182576C07
P577
2012-09-01T00:00:00Z